EGFR and non-small cell lung carcinoma: Besides data based on 73 matched pre/post-osimertinib cfDNA analysis in the AURA3 trial, one recent study presented a series of 35 matched pre-post treatment biopsies obtained from patients with EGFR-mutant NSCLC treated with osimertinib in second-line therapy [69,70].